StoxIpca Laboratories vs Sai Life Sciences: share price & financials comparison
NSE: IPCALAB vs SAILIFE · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Ipca Laboratories vs Sai Life Sciences at a glance
Ipca Laboratories (IPCALAB) has a market capitalisation of ₹47,797 Cr, against ₹40,972 Cr for Sai Life Sciences (SAILIFE). Over the past year Sai Life Sciences has returned +108.9%, compared with +45.5% for Ipca Laboratories. On valuation, Ipca Laboratories trades at a lower P/E of 34.1 versus 202.3. Ipca Laboratories earns a higher return on equity (16.2% vs 7.5%). Ipca Laboratories comes out ahead on size, valuation, profitability and financial health. Sai Life Sciences comes out ahead on growth, momentum and technicals. Across the scored metrics below, Ipca Laboratories leads on 6 and Sai Life Sciences on 6. On StoxGud's 10-point checklist, Ipca Laboratories scores 8/10 and Sai Life Sciences scores 6/10.
| Metric | Ipca Laboratories | Sai Life Sciences |
|---|---|---|
| Size | ||
| Market cap | ₹47,797 Cr | ₹40,972 Cr |
| Revenue (latest FY) | ₹9,646 Cr | ₹2,192 Cr |
| Net profit (latest FY) | ₹1,141 Cr | ₹349 Cr |
| Valuation | ||
| P/E | 34.1 | 202.3 |
| P/B | 5.51 | 15.24 |
| Dividend yield | 0.11% | — |
| Profitability | ||
| Return on equity | 16.2% | 7.5% |
| Net profit margin | 13.4% | 8.5% |
| Operating margin | 22.5% | 29.5% |
| Growth | ||
| Revenue growth (YoY) | +13.8% | +22.5% |
| Net profit growth (YoY) | +32.8% | — |
| Revenue CAGR (multi-year) | +12.2% | — |
| Financial health | ||
| Debt to equity | 0.07 | 0.17 |
| Momentum | ||
| 1-month return | -1.8% | +31.9% |
| 1-year return | +45.5% | +108.9% |
| 3-year CAGR | +21.3% | — |
| 5-year CAGR | +11.4% | — |
| 10-year CAGR | +21.4% | — |
| Distance from 52W high | -6.2% | +0.0% |
| Technicals | ||
| RSI (14) | 38 | 93 |
| Price vs 200-day avg | +11.2% | +56.3% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Ipca Laboratories | Sai Life Sciences |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 8/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Ipca Laboratories or Sai Life Sciences?
Ipca Laboratories has a market cap of ₹47,797 Cr and Sai Life Sciences has a market cap of ₹40,972 Cr as of 13 Nov 2026.
Which has a lower P/E, Ipca Laboratories or Sai Life Sciences?
Ipca Laboratories has the lower P/E: Ipca Laboratories trades at 34.1 and Sai Life Sciences at 202.3.
Which gave better returns in the last year, Ipca Laboratories or Sai Life Sciences?
Sai Life Sciences did better: Ipca Laboratories returned +45.5% and Sai Life Sciences returned +108.9% over one year.
What is the difference between Ipca Laboratories and Sai Life Sciences?
Both are NSE-listed companies in Healthcare. Ipca Laboratories is about 1.2 times the size of Sai Life Sciences by market cap. In the latest financial year Ipca Laboratories reported revenue of ₹9,646 Cr and Sai Life Sciences ₹2,192 Cr. Operating margin is 22.5% for Ipca Laboratories and 29.5% for Sai Life Sciences. Debt to equity is 0.07 for Ipca Laboratories and 0.17 for Sai Life Sciences.
Which is better, Ipca Laboratories or Sai Life Sciences?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Ipca Laboratories leads on 6 and Sai Life Sciences on 6. Ipca Laboratories is ahead on size, valuation, profitability and financial health. Sai Life Sciences is ahead on growth, momentum and technicals. On StoxGud's rules-based checklist Ipca Laboratories scores 8/10 and Sai Life Sciences scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.